Cibus (CBUS) Operating Expenses (2016 - 2026)
Cibus (CBUS) posted Operating Expenses of $23.6 million for Q4 2025, up 47.21% sequentially from $16.1 million in Q3 2025, and up 22.85% YoY from $19.2 million in Q4 2024.
Cibus (CBUS) Operating Expenses (2016 - 2026) Analysis & Trends
Cibus has reported Operating Expenses for 10 years, with the latest figure at $23.6 million in Q4 2025.
- Quarterly Operating Expenses rose 22.85% year-over-year to $23.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $101.2 million (down 61.48% YoY) and the FY2025 annual result came in at $101.2 million, down 61.48% from the prior year.
- Operating Expenses rose to $23.6 million in Q4 2025 per CBUS's latest filing, from $16.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $270.4 million in Q4 2023 and troughed at $3.4 million in Q4 2022.
- A 5-year average of $36.7 million and a median of $17.5 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 7960.06% in 2023, then sank 92.89% in 2024.
- Over 5 years, Operating Expenses stood at $6.6 million in 2021, then tumbled by 49.54% to $3.4 million in 2022, then soared by 7960.06% to $270.4 million in 2023, then tumbled by 92.89% to $19.2 million in 2024, then advanced by 22.85% to $23.6 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $23.6 million, $16.1 million, and $18.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | 13.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.92 Mn |
| Dec 31, 2025 | 23.63 Mn |
| Sep 30, 2025 | 16.05 Mn |
| Jun 30, 2025 | 18.88 Mn |
| Mar 31, 2025 | 42.61 Mn |
| Dec 31, 2024 | 19.24 Mn |
| Sep 30, 2024 | 202.10 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Mar 31, 2024 | 19.00 Mn |
| Dec 31, 2023 | 270.42 Mn |
| Sep 30, 2023 | 26.27 Mn |
| Jun 30, 2023 | 19.51 Mn |
| Mar 31, 2023 | 4.51 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 6.25 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 6.12 Mn |
| Dec 31, 2021 | 6.65 Mn |
| Sep 30, 2021 | 6.44 Mn |
| Jun 30, 2021 | 6.34 Mn |